315.472.7504

Current Clinical Trials

How to Participate/Find a Trial

If you want to discuss clinical research trials, and you are already a patient, ask your provider at your next visit. Alternatively, or If you are not a current patient, you can call the HOA Research Department at 315-472-7504, extension 1350.

A list of HOA’s current clinical trials that are recruiting new patients is below. The list is grouped by disease.

If you are looking for a trial that is not listed here, please contact us as we may be able to open a trial for eligible patients.

For a complete list of all available clinical trials nationwide, visit ClinicalTrials.gov, a website maintained by the National Institutes of Health -- which is the research arm of the Department of Health and Human Services.

Breast

Breast, A012303, Shortstop-HER2

ClinicalTrials.gov ID: NCT06876714

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.

Breast, ASCENT-05/ GS-US-595-6184/ AFT-65

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Breast, Cambria-2 D8535C00001

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).

Breast, JZP598-208

ClinicalTrials.gov ID: NCT07102381

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer.

Breast, NRG-BR007

DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18

Breast, OptimICE-pCR: A012103

This phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab.

Breast, Personalis, 01-PS-001

ClinicalTrials.gov ID NCT06230185

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

Breast, STML-ELA-0422 “ELEGANT”

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), S1925

Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with CLL/SLL

Colorectal

Colorectal, MCLA-158-CL01 “MERUS”

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in mCRC

Esophageal

Esophageal, MK3475-06B-05 “KEYMAKER-U02”

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants with Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B.

Immunotherapy

Immunotherapy, A151804

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Lung

Lung, 61186372NSC2012 “Copernicus”

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Lung, A081801

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

Lung, D702GC0000, Artemide-Lung04

ClinicalTrials.gov ID NCT06868277

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer.

Lung, D763QC00001, Tropion-Lung17

ClinicalTrials.gov ID: NCT07291037

A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Lung, Merck V940 INTerpath-009

ClinicalTrials.gov ID: NCT06623422

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy.

Lung, MIRATI 849-017 “KRYSTAL 17”

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Lung, NRG-LU007

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Lung, Ovation-23-001

The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in these patient populations.

Lung, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Lung, Tempus Gemini TP-CA-002

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Lymphoma

Hodgkin Lymphoma, AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.

Lymphoma, GO45434

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.

Mantel Cell

Mantel Cell, A052101

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated.)

Melanoma

Melanoma, A091903

This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.

Multiple Myeloma

Multiple Myeloma, EAA173

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Multiple Myeloma, Equate EAA181

Effective Quadruplet Utilization after Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation.

Multiple Myeloma, MajesTEC-7 64007957MMY3005

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Prostate

Prostate, Viper, URCC 22053

ClinicalTrials.gov ID: NCT05838716

This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.

Renal

Renal, A032201 “STRIKE”

ClinicalTrials.gov ID NCT06661720

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC).

Solid Tumor

Solid Tumor, ART0380C001 “ARTIOS”

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors.

Solid Tumor, S1937

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Urothelial

Urothelial, S1937

ClinicalTrials.gov ID: NCT04579224

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Brittonfield - E. Syracuse, NY

5008 Brittonfield Parkway
East Syracuse, NY 13057

5490 Cobbler Way
Camillus, NY 13031

Health Central Building
37 West Garden Street
Suite 301
Auburn, NY 13021

Wellness Center

5490 Cobbler Way
Camillus, NY 13031

Hematology-Oncology Associates CNY provides cancer treatment, hematology services, access to clinical research trials, therapeutic infusion services, diagnostic imaging, and cancer screening to patients primarily in Central New York, including the Syracuse area, Utica, Oneida, Verona, Watertown, and Oswego, New York.

©2026 HOA - Privacy Policy Conflict of Interest Policy Rights and Protections From Surprise Medical Bills